RxDoctor Payments Data

Shane Prejean, MD

Advanced Heart Failure and Transplant Cardiology · Houma, LANPI 1609141985

Payments from drug & device makers

What this record shows

The money is spread across several categories — grants (59.2%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by Edwards Lifesciences at 40.5% of the total. Reporting peaked in 2020 at $63,872 and has fallen 55.8% since, to $28,227 in 2025.

$102,213in general payments, 2019–2025

Across 243 payments — averaging $420.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$41K
  • Novo Nordisk$23K
  • Medtronic$16K
  • Boston Scientific$14K
  • Abbott$5K
  • Angiodynamics, Inc.$674
  • plus $2K from 21 others

What the payments were for

  • Speaking & faculty fees$23,15623%
  • Grants$60,50059%
  • Travel & lodging$6,9127%
  • Food & beverage$11,64511%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few advanced heart failure and transplant cardiology providers in Louisianato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$882,837
Medicare patients
1,115
Services billed
25,331

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis17$582,830
EliquisApixaban499$473,045
JardianceEmpagliflozin223$213,389
CamzyosMavacamten23$183,559
EntrestoSacubitril/Valsartan138$162,589
OzempicSemaglutide138$161,905
Repatha SureclickEvolocumab120$102,818
XareltoRivaroxaban63$71,570
Repatha PushtronexEvolocumab48$45,725
MounjaroTirzepatide25$30,895
BrilintaTicagrelor33$29,664
WegovySemaglutide18$23,545
FarxigaDapagliflozin Propanediol25$17,079
VeltassaPatiromer Calcium Sorbitex15$16,067
Rosuvastatin Calcium1,220$14,361

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$92$1,055,875516 claims
Boehringer IngelheimJardiance$44$213,389223 claims
Novo NordiskOzempic, Wegovy$22,852$185,449156 claims
E.r. Squibb & Sons, L.L.C.Camzyos$226$183,55923 claims
Johnson & JohnsonXarelto$14$71,57063 claims
AstraZenecaBrilinta, Farxiga$125$46,74358 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in Louisianaon file to place this against a meaningful peer group, so we don't.

Other advanced heart failure and transplant cardiology in Houma

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →